World

Protests against Dutch nominee as EU climate commissioner

Sep 01, 2023

The Hague [Netherlands], September 1: The nomination of Dutch Foreign Minister Wopke Hoekstra as the new European Union commissioner for climate action has been met with increasing opposition in the Netherlands.
An online petition created by the citizens' movement De GoedeZaak (The Good Cause) to oppose Hoekstra's appointment had been signed by more than 30,000 people on Thursday.
There is also criticism within Hoekstra's own party, the Christian Democratic Appeal (CDA), as well as from environmental organizations.
The petition calls on parliament to nominate a candidate who takes climate change seriously.
Hoekstra, who used to work for the Shell oil company, has not distinguished himself as a protector of the climate, neither as finance minister nor as foreign minister, the citizens' movement said.
"Although Hoekstra has neither the knowledge, skills nor the will to act against a total climate catastrophe, he of all people is nominated as EU commissioner," the group said.
The foreign minister is to succeed fellow Dutchman Frans Timmermans, who is the leading candidate of the coalition between his Labour Party and the Greens in the upcoming parliamentary elections set for November in the Netherlands.
Dutch Prime Minister Mark Rutte had proposed Hoekstra for the post.
European Commission President Ursula von der Leyen nominated Hoekstra on Tuesday. He must now receive the approval of the European Parliament.
Source: Qatar Tribune

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025